Predicting Development of SCAF in Device Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation

About this trial

Atrial fibrillation (AF) often starts with short episodes of rapid irregular heartbeats that are only detected by implanted pacemakers or defibrillators. Usually people don't know that they have these episodes. Over time, these episodes can happen more often and last for longer periods. In some people, the heart eventually remains permanently in a fast irregular rhythm, known as atrial fibrillation. This condition can lead to strokes and blood clots. If physicians could detect atrial fibrillation at a very early stage they could treat people early and possibly prevent the condition from becoming permanent. People with implanted devices allow a unique opportunity to constantly monitor the heart rhythm so investigators can detect any irregularities immediately.

Investigators don't know which people are at risk of developing short episodes of fast irregular heartbeats that can lead to atrial fibrillation. The purpose of this study is to find out if there are proteins or chemical changes in the blood that can predict the risk of developing atrial fibrillation. These chemical changes, also known as biomarkers, may also be able to give investigators other clues about atrial fibrillation.

Eligibility criteria

Qualifiers

None

Disqualifiers

Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter)

Participants considered by the investigator to be unsuitable for the study for the following reason: life expectancy less than 2 years due to concomitant disease

Participants who are pregnant or breast-feeding

Congenital heart disease

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
University of Ottawa Heart InstituteK1Y 4W7, OttawaOntario, Canada

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Genome Canada

Collaborator